BioSpace News Archive

Biotech Beach

AltaMed Health Services Corporation Notifies Patients of Data Security Incident

AltaMed Health Services Corporation (“AltaMed”) has become aware of a data security incident experienced by its business associate, Sharecare Health Data Services (“SHDS”), that may have involved the personal and protected health information of some of its patients.

February 15, 2019

·

2 min read

Drug Development

Lundbeck and Otsuka’s Antipsychotic Drug Rexulti Fails Two Bipolar Phase III Trials

Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder.

February 15, 2019

·

2 min read

·

Mark Terry

Policy

New Government Funding Bill Provides FDA With Additional $269 Million

If the new funding bill is signed by the president, the FDA will have some extra funds to support various initiatives.

February 15, 2019

·

2 min read

·

Alex Keown

Job Trends

With New HQ, Boston’s Medidata Expects to Hire 600-800 Over Next 5 Years

“This is Medidata’s first office in Boston, and the company is excited for the opportunity over the next several years to tap into the amazing life sciences and technology skills that Boston can offer,” said Medidata’s chief people officer.

February 15, 2019

·

2 min read

·

Mark Terry

Policy

Insys Trial Continues With Notorious Rap Video Played for Jurors

A rap video extolling the virtues of prescribing a powerful fentanyl-based pain killer to patients beyond what the drug was initially intended, is coming back to haunt Insys founder John Kapoor.

February 15, 2019

·

3 min read

·

Alex Keown

Business

LenioBio Announces a Scientific Advisory Board Composed of Experts within the Field of Biotechnology

LenioBio GmbH announces the appointment of Dr. Lorenz M. Mayr, Prof. Govind Rao, and Prof. Stefan Schillberg to LenioBio’s Scientific Advisory Board (SAB).

February 15, 2019

·

3 min read

Business

With 5 Gene Therapies Licensed From Penn, Passage Bio Launches With $115.5 Million Series A

Philadelphia-based Passage Bio launched with a Series A financing round worth $115.5 million. It was led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.

February 15, 2019

·

2 min read

·

Mark Terry

Drug Development

Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.

February 15, 2019

·

3 min read

·

Alex Keown

Pharm Country

WHO Plans to Develop Oversight Standards for Gene Editing Following Chinese Researcher’s Experiment

Following international concern and outrage over a gene editing treatment of human embryos in China, the World Health Organization is taking action.

February 15, 2019

·

2 min read

·

Alex Keown

FDA

FDA Action Alert: Alexion, Stemline Therapeutics and Incyte

Two of the three drugs that were up for review in mid- to late-February received much earlier approval in December 21, the day before the federal government shutdown. The shutdown ended on January 25, 2019.

February 15, 2019

·

4 min read

·

Mark Terry